Prognostic Value of uPA and p53 in Breast Cancer
Author Information
Author(s): Broët P, Spyratos F, Romain S, Quillien V, Daver A, Ricolleau G, Rallet A, Toulas C, Asselain B
Primary Institution: Institut Curie
Hypothesis
The study aims to assess the prognostic value of urokinase plasminogen activator (uPA) and p53 levels in primary breast cancer.
Conclusion
High levels of uPA are associated with shorter survival and disease-free intervals in breast cancer patients.
Supporting Evidence
- High levels of uPA were associated with shorter disease-specific survival.
- 5-year survival rates were significantly lower in patients with high uPA and p53 levels.
- In node-negative patients, high uPA levels were strongly related to worse outcomes.
Takeaway
This study found that measuring certain proteins in breast cancer can help predict how long patients might live without their cancer coming back.
Methodology
A retrospective multicentre study using an automatic quantitative luminometric method to assess uPA and p53 levels in breast cancer samples.
Limitations
The prognostic value of p53 was limited when uPA was included in multivariate analysis.
Participant Demographics
Patients were operable breast cancer patients from seven French institutions.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website